Literature DB >> 8126115

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.

S Dauvois1, R White, M G Parker.   

Abstract

The mouse estrogen receptor was shown to be constantly shuttling between the nucleus and cytoplasm although under steady-state conditions it is detected predominantly in the cell nucleus in both the absence and presence of estradiol. Shuttling was demonstrated by monitoring the transfer of protein between nuclei in heterokaryons and by examining the subcellular distribution of mutant receptors. In the presence of the partial antiestrogen 4-hydroxytamoxifen the receptor was retained in the nucleus whereas it accumulated in the cytoplasm when cells were treated with the pure antiestrogen ICI 182780. The effect of the pure antiestrogen was to inhibit nucleocytoplasmic shuttling of the receptor by blocking its nuclear uptake. Thus although ligand binding is not required by the estrogen receptor to undergo nucleocytoplasmic shuttling, this process can be disrupted by the binding of a pure antiestrogen.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8126115     DOI: 10.1242/jcs.106.4.1377

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  108 in total

1.  Oestrogen-dependent expression of the SM2 smooth muscle-type myosin isoform in rabbit myometrium.

Authors:  A Capriani; A Chiavegato; R Franch; G Azzarello; O Vinante; S Sartore
Journal:  J Muscle Res Cell Motil       Date:  1997-08       Impact factor: 2.698

2.  Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells.

Authors:  Simona Caporali; Manami Imai; Lucia Altucci; Massimo Cancemi; Silvana Caristi; Luigi Cicatiello; Filomena Matarese; Roberta Penta; Dipak K Sarkar; Francesco Bresciani; Alessandro Weisz
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

3.  Activation of central, but not peripheral, estrogen receptors is necessary for estradiol's anorexigenic effect in ovariectomized rats.

Authors:  Heidi M Rivera; Lisa A Eckel
Journal:  Endocrinology       Date:  2010-11-10       Impact factor: 4.736

Review 4.  The future of antihormone therapy: innovations based on an established principle.

Authors:  K Parczyk; M R Schneider
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Characterization of the pharmacophore properties of novel selective estrogen receptor downregulators (SERDs).

Authors:  Karen J Kieser; Dong Wook Kim; Kathryn E Carlson; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2010-04-22       Impact factor: 7.446

Review 6.  Estrogen and progesterone receptors: from molecular structures to clinical targets.

Authors:  Stephan Ellmann; Heinrich Sticht; Falk Thiel; Matthias W Beckmann; Reiner Strick; Pamela L Strissel
Journal:  Cell Mol Life Sci       Date:  2009-03-31       Impact factor: 9.261

7.  Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models.

Authors:  Ping Fan; Wei Yue; Ji-Ping Wang; Sarah Aiyar; Yan Li; Tae-Hyun Kim; Richard J Santen
Journal:  Endocrinology       Date:  2009-01-29       Impact factor: 4.736

8.  Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.

Authors:  Caroline E Ford; Elin J Ekström; Tommy Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists.

Authors:  A Mahfoudi; E Roulet; S Dauvois; M G Parker; W Wahli
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  Cannabinoid ligand-receptor signaling in the mouse uterus.

Authors:  S K Das; B C Paria; I Chakraborty; S K Dey
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.